Back to Stakeholders
Categories

1 domain / 2 areas / 1 specialization

Negev Capital

Data updated

George Town, Cayman Islands

Negev Capital is a venture capital fund focused on CNS and brain-health therapeutics, with a stated strategy centered on seed to Series A investments. The fund says it is domiciled in the Cayman Islands and that key team members are based in Limassol, Cyprus, Vienna, and New York.

It matters in the psychedelic ecosystem because Negev Capital has backed and exited multiple companies in psychedelic-derived and neuropsychiatric drug development, including Gilgamesh Pharmaceuticals, Mindset Pharma, Bright Minds Biosciences, and others. The fund describes its thesis as supporting psychedelic-derived and novel neuropsychiatric compounds that can mature into mainstream therapeutic categories.

Investor Context

Venture Capital

Investment Context

This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.

Public Portfolio Examples

  • Small Pharma Ltdfollow-on / strategic investment - USD 1 million cumulative - Sep 21, 2021

Negev Capital presents itself as a $30M+ biotech venture fund concentrated on CNS and brain-health therapeutics, with emphasis on early-stage companies and capital-efficient drug development. Its portfolio and realized exits show a strong orientation toward psychedelic-derived and adjacent neuropsychiatric assets, spanning compounds for depression, addiction, epilepsy, and other CNS indications. The firm also operates Negev Labs, a venture studio focused on sourcing and building CNS drug candidates with existing human data.

Investor Type

Venture Capital Fund

Geographic Scope

Global

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement

Active

Investment Stage Focus

SeedSeries A/BGrowth / Late Stage

Investment Focus Areas

Drug Development

Investment Orientation

Engagement Status

Active

Investor Type

Venture Capital Fund

Investment Website

Recorded Investments

Small Pharma Ltd

Sep 21, 2021

follow-on / strategic investment - USD 1 million cumulative

Negev Capital said the investment increased its cumulative exposure to Small Pharma to $1 million.

Negev Capital doubled down on its sizable investment in Small Pharma Inc.

Quick Facts

Founded
2021
HQ
George Town, Cayman Islands
Website
Visit